Related Experiment Video
Updated: Apr 19, 2026

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
Published on: March 31, 2023
Diethylaminobenzaldehyde is a covalent, irreversible inactivator of ALDH7A1
Min Luo1, Kent S Gates1, Michael T Henzl2
1†Department of Chemistry, University of Missouri-Columbia, Columbia, Missouri 65211, United States.
Abstract:
There is growing interest in aldehyde dehydrogenases (ALDHs) because of their overexpression in cancer stem cells and the ability to mediate resistance to cancer drugs. Here, we report the first crystal structure of an aldehyde dehydrogenase complexed with the inhibitor 4-diethylaminobenzaldehyde (DEAB). Contrary to the widely held belief that DEAB is a reversible inhibitor of ALDHs, we show that DEAB irreversibly inactivates ALDH7A1 via formation of a stable, covalent acyl-enzyme species.
Insights
Aldehyde dehydrogenases (ALDHs) are linked to cancer stem cells and drug resistance. This study reveals that 4-diethylaminobenzaldehyde (DEAB) irreversibly inactivates ALDH7A1, forming a covalent acyl-enzyme, challenging previous assumptions.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Aldehyde dehydrogenases (ALDHs) are increasingly recognized for their role in cancer stem cells.
- ALDH overexpression is associated with resistance to cancer therapeutics.
- Understanding ALDH inhibition mechanisms is crucial for developing new cancer treatments.
Purpose of the Study:
- To determine the crystal structure of an aldehyde dehydrogenase in complex with the inhibitor 4-diethylaminobenzaldehyde (DEAB).
- To elucidate the mechanism of DEAB inhibition on ALDH7A1.
- To challenge the established understanding of DEAB as a reversible inhibitor.
Main Methods:
- X-ray crystallography to obtain the structure of ALDH7A1 complexed with DEAB.
- Biochemical assays to investigate the inhibitory activity and mechanism of DEAB.
- Mass spectrometry to identify covalent adducts.
Main Results:
- The first crystal structure of an aldehyde dehydrogenase complexed with DEAB was determined.
- DEAB was shown to irreversibly inactivate ALDH7A1.
- A stable, covalent acyl-enzyme intermediate was identified as the product of DEAB inactivation.
Conclusions:
- DEAB acts as an irreversible inhibitor of ALDH7A1, not a reversible one as previously believed.
- The formation of a covalent acyl-enzyme species underlies the irreversible inactivation mechanism.
- These findings necessitate a re-evaluation of DEAB's utility and mechanism in targeting ALDHs for cancer therapy.
Related Concept Videos
Enzyme Inhibition
Dehydration of Aldols to Enals: Base-Catalyzed Aldol Condensation
Ketones with Nonenolizable Aromatic Aldehydes: Claisen–Schmidt Condensation
As the self-condensation of ketones is generally not favored in basic conditions, the self-condensed products do not form in the reaction between ketones and benzaldehyde. The general reaction of Claisen–Schmidt...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Crossed Aldol Reaction Using Weak Bases

